A haemagglutination test for rapid detection of antibodies to SARS-CoV-2.
A haemagglutination test for rapid detection of antibodies to SARS-CoV-2.
复制标题
DOI:
10.1038/s41467-021-22045-y
复制
发表时间:
2021-03-29
影响因子:
16.6
通讯作者:
Joly E
中科院分区:
文献类型:
--
作者:
Townsend A;Rijal P;Xiao J;Tan TK;Huang KA;Schimanski L;Huo J;Gupta N;Rahikainen R;Matthews PC;Crook D;Hoosdally S;Dunachie S;Barnes E;Street T;Conlon CP;Frater J;Arancibia-Cárcamo CV;Rudkin J;Stoesser N;Karpe F;Neville M;Ploeg R;Oliveira M;Roberts DJ;Lamikanra AA;Tsang HP;Bown A;Vipond R;Mentzer AJ;Knight JC;Kwok AJ;Screaton GR;Mongkolsapaya J;Dejnirattisai W;Supasa P;Klenerman P;Dold C;Baillie JK;Moore SC;Openshaw PJM;Semple MG;Turtle LCW;Ainsworth M;Allcock A;Beer S;Bibi S;Skelly D;Stafford L;Jeffrey K;O'Donnell D;Clutterbuck E;Espinosa A;Mendoza M;Georgiou D;Lockett T;Martinez J;Perez E;Gallardo Sanchez V;Scozzafava G;Sobrinodiaz A;Thraves H;Joly E
Serological detection of antibodies to SARS-CoV-2 is essential for establishing rates of seroconversion in populations, and for seeking evidence for a level of antibody that may be protective against COVID-19 disease. Several high-performance commercial tests have been described, but these require centralised laboratory facilities that are comparatively expensive, and therefore not available universally. Red cell agglutination tests do not require special equipment, are read by eye, have short development times, low cost and can be applied at the Point of Care. Here we describe a quantitative Haemagglutination test (HAT) for the detection of antibodies to the receptor binding domain of the SARS-CoV-2 spike protein. The HAT has a sensitivity of 90% and specificity of 99% for detection of antibodies after a PCR diagnosed infection. We will supply aliquots of the test reagent sufficient for ten thousand test wells free of charge to qualified research groups anywhere in the world. Serological detection of antibodies against SARS-CoV-2 can help establish rates of seroconversion. Here the authors develop a red cell agglutination test to detect antibodies against the receptor binding domain for distribution free of charge to qualified research groups.
登录
查看更多内容
影响因子:
64.5
作者:
Walls AC;Fiala B;Schäfer A;Wrenn S;Pham MN;Murphy M;Tse LV;Shehata L;O'Connor MA;Chen C;Navarro MJ;Miranda MC;Pettie D;Ravichandran R;Kraft JC;Ogohara C;Palser A;Chalk S;Lee EC;Guerriero K;Kepl E;Chow CM;Sydeman C;Hodge EA;Brown B;Fuller JT;Dinnon KH 3rd;Gralinski LE;Leist SR;Gully KL;Lewis TB;Guttman M;Chu HY;Lee KK;Fuller DH;Baric RS;Kellam P;Carter L;Pepper M;Sheahan TP;Veesler D;King NP
通讯作者:
King NP
影响因子:
16.8
作者:
Huo, Jiangdong;Le Bas, Audrey;Naismith, James H.
通讯作者:
Naismith, James H.
影响因子:
16.6
作者:
Townsend A;Rijal P;Xiao J;Tan TK;Huang KA;Schimanski L;Huo J;Gupta N;Rahikainen R;Matthews PC;Crook D;Hoosdally S;Dunachie S;Barnes E;Street T;Conlon CP;Frater J;Arancibia-Cárcamo CV;Rudkin J;Stoesser N;Karpe F;Neville M;Ploeg R;Oliveira M;Roberts DJ;Lamikanra AA;Tsang HP;Bown A;Vipond R;Mentzer AJ;Knight JC;Kwok AJ;Screaton GR;Mongkolsapaya J;Dejnirattisai W;Supasa P;Klenerman P;Dold C;Baillie JK;Moore SC;Openshaw PJM;Semple MG;Turtle LCW;Ainsworth M;Allcock A;Beer S;Bibi S;Skelly D;Stafford L;Jeffrey K;O'Donnell D;Clutterbuck E;Espinosa A;Mendoza M;Georgiou D;Lockett T;Martinez J;Perez E;Gallardo Sanchez V;Scozzafava G;Sobrinodiaz A;Thraves H;Joly E
通讯作者:
Joly E
DOI:
10.1016/s1473-3099(20)30634-4
发表时间:
2020-12
期刊:
The Lancet. Infectious diseases
影响因子:
--
作者:
National SARS-CoV-2 Serology Assay Evaluation Group
通讯作者:
National SARS-CoV-2 Serology Assay Evaluation Group
影响因子:
82.9
作者:
Amanat F;Stadlbauer D;Strohmeier S;Nguyen THO;Chromikova V;McMahon M;Jiang K;Arunkumar GA;Jurczyszak D;Polanco J;Bermudez-Gonzalez M;Kleiner G;Aydillo T;Miorin L;Fierer DS;Lugo LA;Kojic EM;Stoever J;Liu STH;Cunningham-Rundles C;Felgner PL;Moran T;García-Sastre A;Caplivski D;Cheng AC;Kedzierska K;Vapalahti O;Hepojoki JM;Simon V;Krammer F
通讯作者:
Krammer F